Market Place
Sourcing Support
HARMONi-A OS Data for Ivonescimab in EGFRm NSCLC at SITC 2025
31 Oct 2025 //
BUSINESSWIRE
Ivonescimab OS Data in EGFR+ NSCLC to Be Presented at SITC 2025
30 Oct 2025 //
PR NEWSWIRE
Summit Therapeutics Raises $500 Million In Private Placement
22 Oct 2025 //
BUSINESS WIRE
Summit Targets 2025 FDA Application For Ivonescimab Post
21 Oct 2025 //
BIOSPACE
Akeso, Summit PD-1/VEGF Blocker Exceeds Survival Expectations
20 Oct 2025 //
BIOSPACE
Cadonilimab Shows OS Gain In 1st-Line Advanced Gastric Cancer
19 Oct 2025 //
PR NEWSWIRE
HARMONi-6 Shows 11.1-Month mPFS, HR=0.6 at ESMO & Lancet
19 Oct 2025 //
PR NEWSWIRE
Akeso, Summit`s Ivonescimab Beats PD-1 In Chemo Combo In 1L NSCLC
19 Oct 2025 //
FIERCE BIOTECH
Ivonescimab Phase III Study Accepted By The Lancet For ESMO 2025
16 Oct 2025 //
PR NEWSWIRE
HARMONi-6 Ivonescimab + Chemo Vs Tislelizumab In 1L NSCLC At ESMO
24 Sep 2025 //
BUSINESSWIRE
Akeso Doses First Patient In Ph 2 AK130 Combo Trial For Cancer
22 Sep 2025 //
PR NEWSWIRE
Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA
22 Sep 2025 //
PR NEWSWIRE
Akeso Initiates $3M Expansion, Driving China`s Biotech Growth
17 Sep 2025 //
BIOSPACE
Akeso Starts Global Cadonilimab Trial in Resistant Liver Cancer
15 Sep 2025 //
PR NEWSWIRE
Akeso Completes Ph3 Enrollment for Ivonescimab in Biliary Cancer
02 Sep 2025 //
PR NEWSWIRE
Akeso, Summit`s PD-1xVEGF drug meets OS goal for the first time
27 Aug 2025 //
FIERCE PHARMA
Akeso Reports Record High Commercial Sales in 2025 Interim Result
26 Aug 2025 //
PR NEWSWIRE
Akeso Scores Twice in Phase 3, Tees up Regulatory Submission
26 Aug 2025 //
FIERCE BIOTECH
First Patient Dosed in Cadonilimab Ph 3 Trial for Gastric Cancer
20 Aug 2025 //
PR NEWSWIRE
Akeso Completes 1st Dosing in Ph III Ivonescimab Trial for NSCLC
30 Jul 2025 //
PR NEWSWIRE
NMPA Accepts sNDA for Ivonescimab Combo in Advanced Lung Cancer
28 Jul 2025 //
PR NEWSWIRE
Akeso Begins Phase III Trial of Ivonescimab for Pancreatic Cancer
23 Jul 2025 //
PR NEWSWIRE
Akeso Begins Phase III Trial of Ivonescimab for Colorectal Cancer
15 Jul 2025 //
PR NEWSWIRE
Akeso Launches First Bispecific ADC in Clinical Trials
03 Jul 2025 //
PR NEWSWIRE
ASCO 2025: Cadonilimab Data in Advanced Cervical Cancer
15 Jun 2025 //
PR NEWSWIRE
Akeso`s Cadonilimab Approved for First-Line Cervical Cancer Treat
04 Jun 2025 //
PR NEWSWIRE
Summit shares results from ivonescimab`s first global ph. 3 trial
30 May 2025 //
FIERCE PHARMA
Akeso’s Anniko enters crowded US PD-1 market
25 Apr 2025 //
FIERCE PHARMA
Summit stock drops on Akeso bispecific OS data vs. Keytruda
25 Apr 2025 //
FIERCE PHARMA
Summit’s Beats Yet Another Cancer Med, Pressuring Keytruda
24 Apr 2025 //
BIOSPACE
Akeso`s Biologic Penpulimab Receives Suppl Approval in US
23 Apr 2025 //
FDA
Akeso`s Ebdarokimab Approved in China for Plaque Psoriasis
21 Apr 2025 //
PR NEWSWIRE
Akeso`s 2024 Results: Competitiveness with Bispecific Antibodies
30 Mar 2025 //
PR NEWSWIRE
Akeso to Host 2024 Financial Results Call on March 31, 2025
28 Mar 2025 //
PR NEWSWIRE
Akeso`s Penpulimab Approved for Nasopharyngeal Cancer
16 Mar 2025 //
PR NEWSWIRE
Akeso Completes Ph3 Enrollment Of Cadonilimab In High-Risk HCC
05 Mar 2025 //
PR NEWSWIRE
Akeso Highlights Summit Therapeutics and Pfizer Collaboration
24 Feb 2025 //
PR NEWSWIRE
Akeso Enrolls First Patient In Ph 3 Ivonescimab Trial For TNBC
20 Feb 2025 //
PR NEWSWIRE
Akeso Enrolls First Patient In Ph 3 Cadonilimab Trial For NSCLC
12 Feb 2025 //
PR NEWSWIRE
Akeso Received Payment for Development Collab on Tagitanlimab
22 Jan 2025 //
PR NEWSWIRE
Cadonilimab Ph 3 Data Publish In Nature Medicine For Gastric Cancer
22 Jan 2025 //
PR NEWSWIRE
Akeso To Share Strategy At 43rd J.P. Morgan Healthcare Conference
06 Jan 2025 //
PR NEWSWIRE
Akeso’s Cadonilimab Therapy Showcased at Lung Cancer Summit
04 Dec 2024 //
PR NEWSWIRE
Akeso To Present At Citi & Evercore 2024 Healthcare Conferences
28 Nov 2024 //
PR NEWSWIRE
Akeso`s Cadonilimab & Ivonescimab in China’s Reimbursement List
27 Nov 2024 //
PR NEWSWIRE
Akeso`s Penpulimab Combo for Hepatocellular Carcinoma Accepted by NMPA
22 Nov 2024 //
PR NEWSWIRE
Akeso Biopharma to Attend Jefferies and Morgan Stanley Events
18 Nov 2024 //
PR NEWSWIRE
Akeso Presents AK132 CLDN18.2/CD47 MoA at SITC 2024
07 Nov 2024 //
PR NEWSWIRE
Akeso Enrolls 1st Patient in Ivonescimab Biliary Tract Cancer Trial
31 Oct 2024 //
PR NEWSWIRE
Akeso Enrolls First Patient in Phase 3 HNSCC Trial with Ivonescimab
30 Oct 2024 //
PR NEWSWIRE
Akeso Phase 3 Study Shows Positive Results In Cervical Cancer
16 Oct 2024 //
PR NEWSWIRE
Akeso Secures $250M USD For Global Expansion
13 Oct 2024 //
PR NEWSWIRE
Akeso`s Cadonilimab Receives Approval For 1st-Line Gastric Cancer
30 Sep 2024 //
PR NEWSWIRE
Akeso, Summit`s PD-1 Bispecific Outperforms Keytruda In Lung Cancer
09 Sep 2024 //
FIERCE PHARMA
Akeso Reports 2024 First Half Results, Advancing IO Bispecifics
28 Aug 2024 //
PR NEWSWIRE
Ivonescimab Gets Priority Review For First-Line NSCLC Treatment In China
14 Aug 2024 //
PR NEWSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
First Patient Enrolled In US Phase 2 Trial Of Ligufalimab Combo
05 Aug 2024 //
PR NEWSWIRE
NMPA Accepts Akeso`s sBLA For Ivonescimab In 1L PD-L1 Positive NSCLC
29 Jul 2024 //
PR NEWSWIRE
Merck CMO talks Akeso, Summit`s Keytruda head-to-head win
04 Jun 2024 //
FIERCE PHARMA
